P-0251 - Bevacizumab in the first line therapy of metastatic colorectal cancer in olderpatients, study AVEX in clinical practice

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Geriatric Oncology
Colon Cancer
Rectal Cancer
Presenter Lenka Ostrizkova
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors L. Ostrizkova, Z. Mechl, D. Brancikova, O. Bednarik, M. Protivankova
  • University Hospital, Brno/CZ



In Czech republic, according the demographic development, i.e. growing of the population, prolonging of the median of the life, the number of seniors is increasing. 14% of population has 65 years or more. There is a high prevalence of colorectal cancer in this age group. Number of older patients with colorectal cancer is in the oncological consulting rooms permanently increasing. With considering the possibilites of therapy it is necessary to have in mind all risk factors, which are multiplied by age and comorbidities. The study AVEX is the first phase 3 randomized study, with the goal of using systemic chemotherapy and targeted VEGR therapy in seniors with metastatic colorectal cancer. The aim of the study is not only to evaluate the efficacy of the combined chemotherapy + anti VEGF therapy, but the safety of the combined therapy as well.


In the retrospective study from the oncological center of the University Hospital in Brno, are compared own results with them, from published similar clinical studies.


From the year 2009 in the first line of metastatic colorectal cancer 261 patients were treated, out of them 111 were older than 65 years. (38,5% RAS wild type, BRAF non mutated). The therapy used was combination of bevacizumab + capecitabine. In the older patients the overall survival was 18,6 months, time to progression 11, 1 months. Incidence of adverse events was hypertension gr. 2 in 5%, proteinuria gr. 2 in 3% of treated patients.


Our data were not different from those published in the study AVEX and confirm the efficacy and safety of the combination of bevacizumab and capecitabin as a first-line treatment of metastatic colorectal cancer in older patients, regardless the RAS and BRAF mutation.